1. Home
  2. Analysis
  3. Lenvima
  4. Tecentriq

Lenvima and Tecentriq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lenvima (lenvatinib mesylate) and Tecentriq (atezolizumab). Common drug interactions include pyrexia among females and interstitial lung disease among males.

The phase IV clinical study analyzes what interactions people have when they take Lenvima and Tecentriq. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Lenvima?

Lenvima has active ingredients of lenvatinib mesylate. eHealthMe is studying from 21,113 Lenvima users. Check the latest studies of Lenvima.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

On Aug, 08, 2026

20 people who take Lenvima and Tecentriq together, and have interactions are studied.

Lenvima and Tecentriq drug interactions.

What are the common drug interactions of Lenvima and Tecentriq, by gender? *:

female:

  1. Pyrexia (fever)
  2. Blood creatinine increased
  3. Blood pressure increased
  4. Death
  5. Dehydration (dryness resulting from the removal of water)
  6. Proteinuria (presence of protein in the urine)
  7. Renal impairment (severely reduced kidney function)
  8. Type 1 diabetes mellitus

male:

  1. Interstitial lung disease
  2. Cardiogenic shock (inadequate circulation of blood)
  3. Gastrointestinal necrosis (destruction of gastrointestinal organ)
  4. Hepatitis (inflammation of the liver)
  5. Inflammatory bowel disease
  6. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
  7. Platelet count decreased
  8. Pyrexia (fever)
  9. Renal impairment (severely reduced kidney function)
  10. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

What are the common drug interactions of Lenvima and Tecentriq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Gastrointestinal necrosis (destruction of gastrointestinal organ)
  2. Small intestinal perforation (hole in small intestine)

60+:

  1. Interstitial lung disease
  2. Pyrexia (fever)
  3. Muscular weakness (muscle weakness)
  4. Blood creatinine increased
  5. Blood immunoglobulin g increased
  6. Blood pressure increased
  7. Death
  8. Dehydration (dryness resulting from the removal of water)
  9. Hepatitis (inflammation of the liver)
  10. Inflammatory bowel disease

What are the existing conditions these people have? *

  1. Hepatocellular Carcinoma (liver cancer): 19 people, 95.00%
  2. High Blood Pressure: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lenvima and Tecentriq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lenvima and Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lenvima:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lenvima and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tecentriq and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lenvatinib mesylate and atezolizumab (the active ingredients of Lenvima and Tecentriq, respectively), and Lenvima and Tecentriq (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.